Ultragenyx Pharmaceutical (RARE) Competitors

Genmab A/S (NASDAQ:GMAB) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, community ranking, media sentiment and dividends.

Which has more risk & volatility, GMAB or RARE?

Genmab A/S has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.

Which has stronger earnings & valuation, GMAB or RARE?

Genmab A/S has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$19.84B	0.69	$631.91M	$1.03	20.19
Ultragenyx Pharmaceutical	$434.25M	8.51	-$606.64M	-$6.47	-6.18

Do analysts recommend GMAB or RARE?

Genmab A/S presently has a consensus price target of $45.20, suggesting a potential upside of 117.31%. Ultragenyx Pharmaceutical has a consensus price target of $92.29, suggesting a potential upside of 130.71%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Ultragenyx Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93

Does the MarketBeat Community favor GMAB or RARE?

Ultragenyx Pharmaceutical received 671 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 77.40% of users gave Ultragenyx Pharmaceutical an outperform vote while only 62.65% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Genmab A/S	Outperform Votes 161 62.65%	Underperform Votes 96 37.35%
Ultragenyx Pharmaceutical	Outperform Votes 832 77.40%	Underperform Votes 243 22.60%

Do insiders and institutionals hold more shares of GMAB or RARE?

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 5.8% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Is GMAB or RARE more profitable?

Genmab A/S has a net margin of 23.49% compared to Ultragenyx Pharmaceutical's net margin of -106.93%. Genmab A/S's return on equity of 14.64% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	23.49%	14.64%	12.37%
Ultragenyx Pharmaceutical	-106.93%	-187.12%	-37.55%

Does the media favor GMAB or RARE?

In the previous week, Ultragenyx Pharmaceutical had 18 more articles in the media than Genmab A/S. MarketBeat recorded 25 mentions for Ultragenyx Pharmaceutical and 7 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.96 beat Ultragenyx Pharmaceutical's score of 0.67 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	7 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ultragenyx Pharmaceutical beats Genmab A/S on 9 of the 17 factors compared between the two stocks.